136ｾ408 縺0106 ﾌ036ﾑ86ｾ4 ﾌ04 ﾇ 罔ﾐ6ﾑ86ｾ4 ｨB080ｸ ｧ90ｷ ｧ8 apple080ｸ7046ｧ ｦ001000ｷ ｹ ｧ9000ｹ ｧ9000ｹ0, 02
|
|
|
- ああす えんの
- 7 years ago
- Views:
Transcription
1 136ｾ46ﾑ8096ﾒ26ﾑ ｦﾐ ﾌ6ｾ ﾒ20308apple08apple086ｧ ｷ fi07020ｷ307 ﾒ0607 6ｦ007080ｸ ﾞ ｧ90ｹ ｧ8 ﾞ apple apple080ｹ ｹ0*, 6ﾑ8apple6ｧ902080ｸ703080ｹ0 ﾒ ｧ80ｹ ｧ9 0ｹ0, ｦﾐ ｧ8 6ｾ ｧ apple ｧ9080ｸ7 ｦﾐ0ｷ ｧ9070ｷ ｹ ｹ0, 6ﾑ8apple6ｧ902080ｸ703080ｹ0 ﾒ ｧ80ｹ0 ﾞ ｸ ｧ80ｹ0, ｦﾐ ｧ8 6ｾ ｧ apple ｧ9080ｸ7 ｦﾐ0ｷ ｧ9070ｷ fi0308 apple ｧ apple ｧ8 apple ｧ ｧ8 07fi04080ｹ0 (09 ﾞ03) fi ｷ ｧ80ｹ ｧ9 0ｹ0 ｮ apple ｧ8 ｯ 07fi ｷ ｷ ｷ ｷ ｹ ｧ80ｹ ｧ80ｹ0. ﾌ ｹ0 00apple06apple fi0ｹ ｹ0 07fi04080ｸ applefi ｦ00ｹ0 apple ｹ0 020ｷ307 0ｸ7applefi 閨0209 apple ｸ , ｹ applefi 02060ｹ fi 080ｸ70ｹ ｹ ｷ304090ｹ0. 縺06 apple , 08 00apple06apple fi0ｹ ｹ0 09 ﾞ03 006ｧ apple ｹ ｸ70ｹ0 ﾞ ｧ80ｹ ｷ3096ｧ80ｹ0 ﾞ ｦ00ｹ ｦ ｸ70ｹ apple 07fi080ｷ307080ｸ70ｹ ｸ702086ｦ00ｹ0, fi0ｹ0 apple080ｸ7 00apple ｧ ｧ ｹ0 applefi ｦ apple6ｧ9- apple020ｷ30409 apple 03 09fi07020ｷ ｦ007080ｸ ｧ80ｹ0 07fi04080ｸ7 ( ﾒ ﾞ03), fiapple0ｷ30ｹ ｹ ｧ802090ｹ0, 09 0ｸ7apple 閨 apple 040ｸ ｧ9. [1] 縺 , ｸ70407fi ｹ0 07fi04080ｸ7 006ｧ ｦ ｸ70ｹ ｹ ｸ ｧ9. [1] ﾇ 09 ﾞ ｷ303006ｧ ｷ30ｹ ｧ8030ｷ ｹ0 040ｸ ｧ80ｹ ｸ ｧ80ｹ0 07fi04080ｸ7 apple080ｸ7 閨 ﾑ ｧ8 07fi04080ｹ ｧ fi- 070ｷ307. ﾌ 04080ｸ fi ｹ0 006ｧ ｹ0 ( ﾞ08ｦﾐ, ankle-brachial index) 閨 ｧ9 0ｷ30ｹ ｧ ｸ7 6ｧ ｧ8 00 閨 ｹ ｷ ｹ0 09 ﾞ ｷ303006ｧ ｧ ｹ ｸ700 閨07090ｹ ｷ ｷ304090ｹ0. [2] 0903fi 閨07 applefi apple ｧ ｧ8 REACH 00apple ｧ ｸ707 fi0206 apple fi applefi % 020ｷ ﾞ03 006ｧ 閨0ｹ ｧ ｹ ｧ9 0ｹ0 6ｧ ｧ80ｹ0 07fi04080ｸ7[3] (6ｾ4046ｧ8-00 1). 6ｾ fi0ｹ fi0ｹ0 020ｷ ﾞ03 apple 閨07080ｸ ｷ [4], fi apple fi ｷ3-00 閨 ﾞ apple000ｸ ｧ8 090ｷ3096ｧ apple ｹ0 apple080ｸ ｸ ｧ907-0ｸ ｹ ｸ ｷ307 [5, 6] ｸ ｧ ｧ ﾞ03 (6ｾ4046ｧ800 2) 6ｾ apple fi ｸ70ｹ ｧ90ｹ ﾞ03 006ｧ ｸ700apple020ｷ ｧ 閨02000ｹ0 陦 fi ｹ0 apple fi ｹ0 apple000306apple ｹ0 6ｾ ｧ9 07fi04080ｹ ｧ9apple080ｸ ｷ303fi apple ｧ9 006ｧ ｧ fi0708 閨 fi apple fi ｧ9- ｨB apple06 006ｧ9070ｷ ｹ0 040ｸ700apple020ｷ ｧ9 0ｹ0 020ｷ ｷ ｷ307 [5, 6]. 0903fi ｧ ｧ9 apple080ｸ ｧ apple ｾ4046ｧ ｾ40ｸ7076ｦ0apple ｷ ｷ ｹ ｷ ｧ80ｹ ｧ9 0ｹ ｧ80ｹ0 07fi04080ｸ7[3]. 00apple apple 03 閨 apple applefi ｸ7-00apple020ｷ ｷ ｧ90ｷ ｧ ｹ ｧ9 0ｹ ｸ 閨03080ｸ70ｹ0. 2. ﾇ 09 ﾞ03 0ｷ30ｹ ｦ ｧ9080ｸ ｦ007080ｸ7 ﾇ apple fi ｧ8030ｷ304090ｹ ｷ apple06apple ｧ ｸ 閨 ｸ70ｹ ｧ90ｹ ﾞ03. ﾌ 026ｧ907 0ｸ707080ｹ ｹ ｹ ｸ7 000ｸ ｧ9080ｸ7 006ｧ apple ｹ0, ｧ907 0ｸ ｹ ｦ ｦ0 00apple ｧ9080ｸ 閨0ｹ ｦ ｹ ｦ apple080ｸ 閨04080ｸ707 apple ｧ apple ﾌ ｧ90ｹ ﾞ 閨04080ｸ 閨0ｹ ｦ ｧ907 0ｸ ｸ ｧ80ｹ fi ｹ 閨0ｹ0 apple0608 0ｸ 閨 ｧ907-0ｸ fi ｹ ｧ9 0ｹ ｸ ｷ ｦ ｧ90ｹ0 apple080ｸ 閨04080ｸ ﾞ03 [1, 2, 9]. ﾌ 026ｧ907 0ｸ707080ｹ ｧ9ｨB ｹ ｦ0 040ｸ ｹ0 006ｧ ｹ0 applefi apple 03080ｸ7046ｧ9 6ｧ8 fi ｸ700apple020ｷ ｷ ｧ9apple080ｸ704 0ｹ0 040ｷ3-03fi ｹ ｧ ｸ 閨07080ｹ0 02fi ｹ0 apple000306apple ｹ ｷ3036ｧ90ｹ0 040ｸ700apple apple080ｸ ｸ7 ﾞ08ｦﾐ. ﾒ ｸ707 鐶pple0006, ｧ90ｹ ﾞ03 apple03 鐶pple ｷ3apple6ｧ9ｨB ｷ30ｹ ｧ90ｹ ｹ0 000ｸ ｦ00ｹ0 apple03fi ｹ0, fiapple0ｷ30ｹ ｧ90ｹ ｷ300 閨 ｧ9 07fi0408 [10] apple000ｸ ｧ8 apple 閨 ﾞ03 6ﾑ80202fi0ｹ0 applefi 02060ｹ0 apple000306apple ｹ0 020ｷ apple080ｸ7 apple03 鐶pple ｷ3apple ｦ007 00apple000609fi07020ｷ30ｹ0 applefi ｸ70309fi, fi0ｹ ｹ0 apple030ｷ ｦ00ｹ ｧ9 0ｹ ｧ apple 03 apple 閨00apple fi ｸ70309fi apple00036ｧ9apple020ｷ ｦ00ｹ ｧ8 020ｷ ｸ7-00apple020ｷ ｷ307 apple apple006ｧ9, apple080ｸ ｧ9-
2 136ｾ408 縺0106 ﾌ036ﾑ86ｾ4 ﾌ04 ﾇ 罔ﾐ6ﾑ86ｾ4 ｨB080ｸ ｧ90ｷ ｧ8 apple080ｸ7046ｧ ｦ001000ｷ ｹ ｧ9000ｹ ｧ9000ｹ0, ｹ fi03080ｸ70ｹ ｸ70ｹ ｧ90ｹ ｧ80209 [11] (096ｧ ｹ0 1). ﾇ 00apple ｧ8 apple 03 閨 apple08apple086ｧ ｷ307 apple 03 09fi07020ｷ ｦ ｦ007080ｸ7 apple080ｸ ｷ300 閨07 0ｸ ｸ ｧ907 0ｸ ﾞ03 006ｧ apple 閨 ] apple06 閨 ｧ80ｹ0[2, (6ｾ4046ｧ800 3) apple6ｧ ｸ7 02 apple076ｧ ｹ0 6ﾒ apple apple ｨB ｧ907-0ｸ ｹ0 09 ﾞ03, apple ｧ8 020ｷ ｸ7026ｧ apple06ｨB6ｧ ｸ7076ｧ ｸ7apple apple ｨB ｧ907 0ｸ apple06 006ｧ9070ｷ304090ｹ ｹ0 6ｧ8 09 0ｸ7apple ｸ704 0ｹ apple ｹ0[13] 0ｸ ｹ ｧ907-0ｸ ｧ8030ｷ304090ｹ ｧ80ｹ ｧ9 0ｹ ｸ 閨03080ｸ70ｹ0 6ｧ8/ ｷ ｦ0. 6ｾ 閨0209 apple ｧ ｹ 閨 ｸ70404 閨 ｸ7 02 apple076ｧ ｹ ｷ ｷ ｧ90ｹ ﾞ03 [14]. ﾞ07026ｧ , apple6ｧ ｸ7 02 apple076ｧ ｹ0 0ｸ apple066 56ｧ90ｷ30409 [15]. 縺 apple6ｧ ｸ7 02 apple076ｧ ｹ0 040ｸ ｸ ｧ8 020ｷ ｸ ｸ703000ｸ apple ｧ ｹ0 6ｧ8/ ｧ ｸ apple 03 09fi ｷ307, fiapple0ｷ30ｹ ｸ7apple03fiapple0608, 02 0ｸ7apple ｧ907090ｹ0, ｹ fi fiapple0ｷ30ｹ ｧ90709 [16] ﾞapplefi ｸ 閨0203, 09 6ｦ ｹ0 040ｷ ｧ80ｹ fi ｹ0 閨 apple ｧ9 fi ｸ700apple020ｷ ｧ9 020ｷ , apple fi 閨04080ｸ ｷ ｧ80ｹ ｧ9 - ｮ ﾞ 0ｸ ｧ9 ｯ ｷ304090ｹ0-040ｸ70404 閨 apple ｦ ﾑ ｧ8 040ｸ700apple020ｷ ｷ307 apple apple006ｧ ｧ90ｷ ｧ8 apple080ｸ7046ｧ ｦ001000ｷ ｹ ｧ9000ｹ ｧ9000ｹ0-6ｾ ｹ ｧ802090ｹ0 6ﾑ8apple006ｧ909080ｸ704 : - ﾒ036ｧ ｧ9 / 09fi07080ｹ apple 0ｸ ｹ0 6ｧ8 縺 apple086 76ｧ9 ﾞ ﾒ ﾞ / 6ﾒ2ｦﾐ ﾞ / Amaurosis Fugax 096ｧ ｹ0 1. ﾞ ﾞ ｸ ｧ80ｹ0 6ﾑ802026ｧ ｹ0 ﾞ ｧ8 ﾞ apple [2,9] ｹ ｧ90ｷ304090ｹ ｹ ｸ fi ｹ ｸ ｧ9080ｸ7, 02090ｹ ｧ90ｷ ｹ ｹ ｸ70ｹ ｧ9 0ｹ0, 02090ｹ0 000ｸ707080ｸ8026ｧ80ｹ0 00apple6ｧ ｹ fi 020ｷ ｸ ｸ70ｹ ｦ00ｹ0 apple ｹ0[17]. 6ｾ402060ｹ0 046ｦ ｹ0 040ｸ ｹ apple ｹ0 020ｷ ﾞ apple ｧ9 apple030ｷ fi 00 閨 apple 03 閨 ｹ0[2, 9]. 6ｾ402060ｹ ｸ7030ｸ707026ｧ ｹ ｧ9000ｹ0 040ｸ ｧ ｧ90200 閨07 apple03fi ｹ0 0ｸ7applefi 00apple6ｧ ｹ ｹ min, 02080ｸ 閨0ｹ apple fi ｹ0 applefi ｹ0 006ｧ fi apple03fi ｹ0 ( ) 040ｷ3036ｧ90ｹ0 00apple6ｧ ｸ 閨0ｹ ｾ ｸ apple 閨 閨 apple086ｧ9 040ｸ ｧ ｹ ｧ90ｹ ｸ700apple020ｷ ｧ8 09 ﾞ03, 00 閨04090ｹ ｧ9 0ｹ , fi ｧ90200 閨 閨0708 apple03fi apple6ｧ80ｹ ｸ7 02 apple076ｧ ｹ ｸ707 0ｸ7 0400fi ｦ ｷ ｧ80ｹ fi ｹ0 ( apple 03 閨 ｹ0, n=441) 006ｧ ｧ90ｹ0 08 閨 ｷ300 閨 ｧ ｸ ｦ ｦ0 ( 閨 ｸ7, n=441). 6ｾ46ｦ000080ｷ apple 閨 ｹ ｹ0, ｹ0 apple 03 閨 ｹ0 apple ｧ ｦ apple ｧ90ｷ304090ｹ ｹ0 00 閨 ｹ ｸ7fi ｹ0 applefi ｹ0 (maximum walking distance, apple fi ｧ90ｷ304090ｹ ｦ 閨 ｸ7 (23% vs 15%; P=0.008). ﾞ0ｸ702fi apple08 fi ｸ7036ｧ90ｷ30ｹ ｦ ｹ0 040ｷ ｧ80ｹ fi ｹ0 [34% 020ｷ ｹ0 apple 03 閨 ｹ0 apple0003apple 02086ｦ apple fi ｹ0 applefi 閨0ｹ vs 25% ｸ7 (P=0.01)]. ﾞ016ｧ9ｨB ｷ303006ｧ9 fi ｹ0 apple 03 閨 ｹ0 12% 020ｷ apple fi03030ｷ fi apple 閨 % 閨 ｸ7 (P=0.43) 3.3. ﾞ apple ｧ8 090ｷ3096ｧ ｹ fi0ｹ 陦 fi ｧ apple ｧ80ｹ0 090ｷ3096ｧ80ｹ0 (020ｸ7apple apple06-036ｧ90709) fi ｸ ｸ ｦ ｦ007080ｸ ｧ90ｹ ﾞ03. 6ｾ ｸ ｸ apple 閨070ｷ , apple080ｸ7 040ｸ700apple 閨 ｸ ｧ90ｹ ｸ700apple020ｷ ｧ8 09 ﾞ03, ｧ apple ｧ80ｹ0 090ｷ3096ｧ80ｹ0 040ｸ ｧ9ｨB ｧ90ｷ % 02080ｸ ｦ007080ｸ ｧ ｧ80ｹ fi ｹ ｦ ｧ ｦ ｸ7[19]. 6ｾ 閨0209 CAPRIE (Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events), ｦ0 020ｷ ｸ700apple ｧ ｧ90ｹ ﾞ03, apple086ｧ ｸ apple08066ｧ ｧ apple06036ｧ90709 (325 mg/0900 閨03 ) 006ｧ apple 閨0309 ( ｷ ｧ8 020ｷ307 0ｸ7apple 閨0ｷ ｹ ｷ ｧ80ｹ ｧ907090ｹ0, 75 mg/0900 閨03 ). ﾇ post-hoc ｸ ｷ ﾞ03 陦 fi ｦ apple06036ｧ ｸ70ｹ ｧ90ｹ0 apple080ｸ7 apple6ｧ apple 閨0309 apple ｧ ｧ90ｷ % 02080ｸ ｦ ｦ007080ｸ ｹ ｹ ｸ7 000ｸ ｧ9-080ｸ7, ｦ ｦ ｦ0 00apple ｧ9080ｸ7 6ｧ fi- 030ｷ ｸ ｷ ｧ80ｹ ｧ9 0ｹ0 (P=0.0028). ﾇ 040ｸ ｧ apple06036ｧ907090ｹ apple 閨 ｦ00ｹ ｧ90ｹ apple apple03086ｦ00ｹ0 apple ｹ ｦ007080ｸ 閨 fi0206 0ｸ7apple0003 閨 ｧ90ｷ ｷ ｸ ｷ307, ｸ apple fi 020ｷ apple06apple [21]. ﾇ ｧ apple ｧ90ｹ ﾞ03 閨 ｸ707080ｸ8026ｧ8 00apple6ｧ fi ｷ ｸ ｷ307, 020ｷ apple 閨04000ｷ ｹ apple ｧ80ｹ0[22]. 6ｾ402080ｸ70ｹ ｧ90ｹ ﾞ03 apple ｧ ｧ apple06036ｧ907090ｹ0 75 mg-325 mg/0900 閨03 6ｧ apple 閨03090ｹ0 75 mg/0900 閨03. ﾇ 00apple ｧ ｸ ｸ7 apple03 鐶pple ｧ ｸ700 閨 ｸ700apple ｦ004000ｹ
3 13046ﾑ8 ﾒ6ﾑ ｦﾐ ﾌ6ｾ ｧ9apple080ｸ704 0ｹ0 040ｷ303fi ｹ ｸ7fi 閨0ｹ0 apple fi ｸ70ｹ ｹ 閨0ｹ0 apple fi ｹ0 090ｸ707 6ｧ902000ｹ ｦ ｸ70ｹ ｦ00ｹ ｧ90ｹ0[30]. 0300fi apple 閨07 00apple ｸ707 fi ｸ7apple ｧ9 閨04080ｸ707 06apple apple fi ｹ0 09 ﾞ03 [12]. 6ｾ4046ｧ ｸ ｧ ｧ ｹ0 apple ｧ80ｹ ｧ80ｹ0 07fi04080ｸ7[2,9] ｹ0, ｧ ｸ ｦ00ｹ fi ｹ0[2, 9] apple080306apple ｧ8 090ｷ3096ｧ8 6ﾑ8apple 閨0ｹ 閨02000ｹ0 陦 fi0206 0ｸ7apple ｧ8 040ｸ70404 閨 ｦ ｸ ｦ007080ｸ7 09 ﾞ ｷ307 00apple06apple 陦0ｷ ｹ ｧ80ｹ0, 02090ｹ0 LDL fi03090ｹ0, ｷ ｸ ｧ90ｷ ｧ ｦ0 09 ﾞ ｷ307 00apple06apple 陦0ｷ ｹ0 HDL fi03090ｹ ｦ ｹ ｧ80ｹ fi03090ｹ mg/dl ｧ907 0ｸ707080ｹ ｹ0 09 ﾞ03 0ｸ % - 10% [23], ｦ ｹ ｸ7 apple09036ｧ902080ｸ ｧ8/ HDL fi fi0ｹ0 026ｧ907 0ｸ ｹ0 09 ﾞ03 0ｸ % [13] apple applefi ｷ , ｧ90ｷ ｷ307 00apple06apple 陦0ｷ ｹ fi03090ｹ ｸ7apple080306apple ｧ ｸ ｧ ｧ8 apple ｸ ｦ0 006ｧ90400 apple ｧ9 fi ｧ8 00apple ｦ 閨 ｷ ｷ ｹ ｧ9000ｹ ｧ9000ｹ0[24] post-hoc ｸ ｷ307 apple ｷ ｹ 閨02090ｹ0 4S (Simvastatin Scandinavian Survival Study) 陦 fi ｧ ｧ907090ｹ ｧ9080ｸ70ｹ ｧ90ｹ ｸ7apple ｧ ｧ90ｷ % 陦 0ｹ0 6ｧ apple06 006ｧ9070ｷ30409 apple030800apple ｸ704 0ｹ ｧ9apple080ｸ704 0ｹ0 040ｷ303fi ｹ0[25] 閨07 applefi 閨0209 Heart Protection Study 陦 fi ｧ90ｹ ﾞN 0ｷ ｦ ｧ fi ｸ70ｹ ｧ90ｹ0 apple080ｸ7 閨04080ｸ ｸ7 006ｧ9 080ｸ70ｹ ｧ8 07fi0408 (00006ｧ90ｷ % 020ｷ ｨBfi070ｷ ｸ ｷ307), applefi 02 00apple6ｧ9- apple00 020ｷ apple06 6ｧ90ｷ applefi apple 03080ｸ7046ｧ ｧ80209 [26]. 6ｾ apple03fi ｹ 閨02000ｹ0 閨04080ｸ707 00apple ｧ8 03 閨 ｹ apple006ｧ9 0ｹ ｧ907000ｹ apple ﾞ ｸ7apple ｧ9 02fi ｧ90ｷ ｷ ｸ700apple020ｷ ｷ307 [27] fi ｦ ｹ0 040ｸ ｧ80ｹ0 00apple066 56ｧ90ｷ304090ｹ0[28]. ﾞ016ｧ9ｨB ｷ303006ｧ9 fi apple006ｧ ｧ ｸ70ｹ ｧ90ｹ ﾞ03 閨 ｸ ｸ8026ｧ8 00apple6ｧ ｸ70ｹ0 006ｧ ｹ ｹ ｧ80ｹ0, ｧ ｹ0 040ｸ ｹ ｹ0 C ｹ0 apple030ｷ302000ｹ107090ｹ0 (CRP). ﾞ0ｸ7026ｧ ｹ ｷ 閨 ｧ9 fi ｸ ｧ9- ｨB ｧ90ｷ ｹ0 040ｸ ｧ80ｹ fi ｹ ｦ ｹ ｦ ｹ0 040ｸ700apple020ｷ ｷ307 00apple066 56ｧ90ｷ ｹ0 0ｸ ｷ [28]. 00apple0ｷ30ｹ ｸ70ｹ ｧ90ｹ ｧ9 07fi0408, 026ｦ ｹ0 0402fi04080ｹ ｹ0 0ｸ7apple080306apple ｧ80ｹ0 090ｷ3096ｧ80ｹ0 006ｧ ｧ90ｷ ｷ307 00apple06apple 陦0ｷ ｹ0 LDL fi03090ｹ ｷ3 applefi 100 mg/dl 6ｧ ｷ3 applefi 70 mg/dl ｧ90ｹ apple08036ｦ0 0ｸ 閨 fi 026ｧ907 0ｸ70708 [29] ｹ ｹ0 0ｸ7apple 閨 ｹ0 ﾇ 040ｸ70404 閨 ｸ7apple 閨 ｹ ﾞ ｷ303006ｧ fi ｸ7036ｧ ｦ ｸ70404 閨 ﾞ ｧ80ｹ0 6ｧ ｧ9-0ｹ0 07fi04080ｸ7. 6ｾ 閨 ｸ7 Framingham, 09 0ｸ7apple 閨 apple08-006ｧ fi0206 0ｸ ｧ907 0ｸ ｸ7apple ｧ9 apple ｹ0 00apple ｦ apple ｦ ｸ70ｹ ｧ90ｹ ﾞ ｸ7046ｧ ｸ ｧ8 00apple6ｧ ｷ apple , fi0ｹ fi0ｹ ｦ004000ｷ307 閨 apple ｧ 閨 ｸ70ｹ apple ｸ7apple ﾞ03 [31]. 6ｾ 閨0209 ﾇ ﾌ066ﾑ8 (Heart Outcomes Prevention Evaluation), apple06apple03fi fi ｹ ｧ90ｷ ｷ ｸ ｷ307 applefi ｧ fi0ｹ ｷ ｧ ｸ apple ｦ0 0007ｨB6ｦ ｸ ｹ ｧ907090ｹ0 ( -096ﾑ8 ﾞ), 02090ｹ apple036ｧ903090ｹ0, 6ｧ ｧ fi 02fi ｸ70ｹ ｧ90ｹ ﾞ03 fi ｸ70ｹ ｧ90ｹ ｹ ｹ ｧ80ｹ0 07fi ｸ7[32]. 6ｾ 閨0209 0ｸ7026ｧ8 020ｸ apple08066ｧ ｧ90ｹ ﾞ03, ｸ70ｹ0 08apple086ｧ9080ｸ70ｹ ｧ apple036ｧ903090ｹ ｧ90ｷ % fi 026ｧ907 0ｸ ｹ ｧ ｹ fi ｹ0 applefi ｧ8 07fi0408 [32]. ﾌ fi ｹ ｸ7apple ｧ80ｹ0 090ｷ3096ｧ80ｹ ｧ9ｨB apple6ｧ ｸ apple06apple 陦0ｷ fi ｷ307 applefi 140/90 mmhg 6ｧ fi ｷ307 applefi 130/80 mmhg ｧ90ｹ ｧ fi ｧ8 07fi0408 [2, 9]. ﾇ ABCD (Appropriate Blood Pressure Control in Diabetics) 陦 fi ｧ apple ｧ80ｹ apple006ｧ9 0ｹ0 (0000 閨 ﾑ8 ﾞ, apple036ｧ90309, 6ｧ 閨 ｷ ｧ8 020ｷ ｦ0030ｷ ｧ9080ｸ7, apple6ｧ90709) apple6ｧ902000ｸ ｷ fi040ｷ ｹ ｸ7apple ｧ80ｹ0 090ｷ3096ｧ80ｹ ｧ ｧ8 040ｸ70404 閨 ｦ ｸ7 ﾞ08ｦﾐ ｸ ｦ007080ｸ ｹ ｧ ｹ fi ｹ0 applefi
4 136ｾ408 縺0106 ﾌ036ﾑ86ｾ4 ﾌ04 ﾇ 罔ﾐ6ﾑ86ｾ4 6ｾ fi0ｹ0 ﾒ6ｧ907 0ｸ707080ｹ0 (RR) 6ｾ4046ｧ ｹ ｦ007080ｸ ｧ80ｹ0 ﾞ apple ｹ0 ｨC 閨07 6ﾑ8apple [5] ｧ8 07fi ｸ70ｹ ｧ90ｹ ﾞ03 [33] ｹ ｹ ｸ ｧ9 0ｹ 閨 apple ｧ ｹ0 陦 fi apple 03080ｸ7046ｧ ｧ ｸ ｧ907 0ｸ ｹ0 09 ﾞ ｧ ｷ300 閨07080ｸ70ｹ0 (07070ｷ3 020ｷ fi070ｷ307) 02 apple 閨0ｹ ｸ7apple 閨 ｸ7apple ｧ9 [12, 23] 閨 apple ｧ ｧ fi apple ｧ apple ｸ ｧ ｦ0- apple080ｸ ｦ0apple080ｸ ｧ907 0ｸ ｸ ｷ ｧ90ｹ0 09 ﾞ03 [34, 35] fi0408, 0400 fi03080ｸ70ｹ ｸ70ｹ ｦ00ｹ ｧ90ｹ0 040ｸ ｧ ｹ ｸ70208ｨB0ｸ703060ｷ300 閨07090ｹ ｧ907090ｹ0 (HbA1C) apple6ｧ9- apple fi applefi 7%, ｹ ｧ ｧ9 020ｷ ｷ307 apple ｧ90ｷ ｸ ｦ007080ｸ ｹ , ｹ ｹ fi ｹ ｷ ｦ0 [2, 9] apple000ｸ 閨0203 6ｾ400 fi03080ｸ70ｹ ｸ70ｹ0 0ｸ7apple 閨 ｸ70ｹ0 6ｧ8 apple 046ｦ ｸ70ｹ ｧ90ｹ ﾞ03 6ｧ ｸ ｸ703 閨0ｹ 閨 ｸ7 040ｷ ｦ ｸ70ｹ0. ﾞ070206apple ｧ8 090ｷ3096ｧ8 applefi 02080ｸ7 0402fi ｹ0 040ｸ fi ｹ0 apple apple ｹ apple06026ｧ ｸ7096ｧ8, apple , ｷ fi006 50ｷ30409, ｹ ｧ90ｹ0 0ｸ ｦ ｦ007080ｸ7 applefi ｹ0 020ｷ ｸ ｷ ｸ7apple ｸ707 apple030808apple 閨0ｹ0, 020ｸ apple 閨07000ｹ 閨02090ｹ ｧ ｹ ｸ 閨03080ｸ70ｹ ｧ ｹ , fiapple0ｷ30ｹ ｸ fi 08016ｦ ｧ apple080ｸ ｸ apple6ｧ9apple ｹ ｸ ｹ107090ｹ fi, ｧ90ｹ ﾞ03. 6ｾ 閨03080ｸ 閨 ｧ9 Health Professionals Follow-up Study, 040ｸ ｧ ｹ0 040ｷ3036ｧ90ｹ0 09 ﾞ03, ｧ8 07fi0408 6ｧ ｧ apple ｸ7036ｧ fi ｷ307 08apple086ｧ90ｷ apple000306apple ｹ0 09 ﾞ03. 6ｾ 閨0209 0ｸ7026ｧ8 06 apple ｧ ｸ70404 閨 ｦ ｹ ｧ80ｹ0 apple03fi ｹ0 080ｸ ｦ 閨080ｹ0 (400 mg/0900 閨03 ) ｸ ｦ007080ｸ ｹ0 09 ﾞ03 (00006ｧ90ｷ %) [36] ｧ90ｷ ｸ ｦ ｦ007080ｸ ｧ90ｹ ﾞ03: ｧ ｸ7 040ｸ ｦ ｦ007080ｸ apple ｧ ｧ apple000ｸ 閨02030ｷ apple ｧ ｧ apple ﾞ03 00apple 閨 ｷ30409, ｧ ｸ7 040ｸ ｦ ｦ007080ｸ apple ｧ8 apple 03 閨 apple08apple086ｧ ｷ307 apple 03 09fi07020ｷ ｦ007080ｸ7[2, 9]. 08apple ｸ ｧ ｹ0 fi apple ｧ apple08apple086ｧ ｷ307 apple 03 09fi ｷ ｦ007080ｸ ｧ90ｹ ﾞ03 apple ｹ0, ｦ ｦ0 00apple ｧ9080ｸ ｧ907 0ｸ fi030ｷ ｸ ｷ307. 6ｾ apple03fi 閨 ﾞ03, ｹ , 閨 fi apple006ｧ apple06036ｧ90709, ｧ907000ｹ0, 6 5- apple 閨0ｹ ﾑ8 ﾞ 040ｸ ｧ9ｨB ｦ ｹ0 00apple066 56ｧ90ｷ304090ｹ0[37]. 6ﾒ2 000ｸ7036ｧ ｸ ｸ ｦ fi apple08030ｸ apple006ｧ ｸ707-0ｸ7 0400fi ｧ8 0ｸ ｸ 閨02030ｷ307 ( , apple6ｧ ｸ7 02 apple076ｧ ｹ0, 00006ｧ90ｷ ｸ7 040ｷ ｦ ｸ70ｹ0) 閨 fi fi ｹ ｧ90ｷ ｸ ｦ ｦ007080ｸ fi ｷ ﾞ ｧ9 [1] Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, Circulation 2004; 110: [2] Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006;113:e [3] Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. Jama 2006; 295: [4] Becker GJ, McClenny TE, Kovacs ME, Raabe RD, Katzen BT. The importance of increasing public and physician awareness of peripheral arterial disease. J Vasc Interv Radiol 2002;13:7-11. [5] Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. Jama 2001;286: [6] Rehring TF, Sandhoff BG, Stolcpart RS, Merenich JA, Hollis HW, Jr. Atherosclerotic risk factor control in patients with peripheral arterial disease. J Vasc Surg 2005;41: [7] McDermott MM, Greenland P, Liu K, Guralnik JM, Criqui MH, Dolan NC, et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. Jama 2001;286: [8] McDermott MM, Liu K, Greenland P, Guralnik JM, Criqui MH, Chan C, et al. Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. Jama 2004;292:
5 13046ﾑ8 ﾒ6ﾑ ｦﾐ ﾌ6ｾ [9] Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, et al. Inter- Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007;33 Suppl 1:S1-75. [10] Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Jama 2001;285: [11] Burns P, Gough S, Bradbury AW. Management of peripheral arterial disease in primary care. BMJ (Clinical research ed 2003;326: [12] Lane JS, Vittinghoff E, Lane KT, Hiramoto JS, Messina LM. Risk factors for premature peripheral vascular disease: results for the National Health and Nutritional Survey, J Vasc Surg 2006; 44:319-24; discussion [13] Aboyans V, Criqui MH, Denenberg JO, Knoke JD, Ridker PM, Fronek A. Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation 2006;113: [14] Lassila R, Lepantalo M. Cigarette smoking and the outcome after lower limb arterial surgery. Acta chirurgica Scandinavica 1988;154: [15] Faulkner KW, House AK, Castleden WM. The effect of cessation of smoking on the accumulative survival rates of patients with symptomatic peripheral vascular disease. The Medical journal of Australia 1983; 1: [16] Rigotti NA. Clinical practice. Treatment of tobacco use and dependence. The New England journal of medicine 2002;346: [17] Stewart KJ, Hiatt WR, Regensteiner JG, Hirsch AT. Exercise training for claudication. The New England journal of medicine 2002;347: [18] Fowler B, Jamrozik K, Norman P, Allen Y, Wilkinson E. Improving maximum walking distance in early peripheral arterial disease: randomised controlled trial. The Australian journal of physiotherapy 2002; 48: [19] Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ (Clinical research ed 2002;324: [20] A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348: [21] Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. The New England journal of medicine 2006;354: [22] Collaborative overview of randomised trials of antiplatelet therapy--ii: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration. BMJ (Clinical research ed 1994;308: [23] Murabito JM, D'Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation 1997;96:44-9. [24] Leng GC, Price JF, Jepson RG. Lipidlowering for lower limb atherosclerosis. Cochrane database of systematic reviews (Online) 2000;CD [25] Pedersen TR, Kjekshus J, Pyorala K, Olsson AG, Cook TJ, Musliner TA, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). The American journal of cardiology 1998;81: [26] Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361: [27] Giri J, McDermott MM, Greenland P, Guralnik JM, Criqui MH, Liu K, et al. Statin use and functional decline in patients with and without peripheral arterial disease. Journal of the American College of Cardiology 2006;47: [28] Schillinger M, Exner M, Mlekusch W, Amighi J, Sabeti S, Muellner M, et al. Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. European heart journal 2004;25: [29] Grundy SM, Cleeman JI, Merz CN, Brewer HB, Jr., Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110: [30] Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: the Framingham Study. Journal of the American Geriatrics Society 1985;33:13-8. [31] Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Archives of internal medicine 1991;151: [32] Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in highrisk patients. The Heart Outcomes Prevention Evaluation Study Investigators. The New England journal of medicine 2000; 342: [33] Mehler PS, Coll JR, Estacio R, Esler A, Schrier RW, Hiatt WR. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation 2003;107: [34] Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. The American journal of cardiology 1995;75: [35] Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352: [36] Merchant AT, Hu FB, Spiegelman D, Willett WC, Rimm EB, Ascherio A. The use of B vitamin supplements and peripheral arterial disease risk in men are inversely related. The Journal of nutrition 2003;133: [37] Feringa HH, van Waning VH, Bax JJ, Elhendy A, Boersma E, Schouten O, et al. Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. Journal of the American College of Cardiology 2006;47:
13 ﾒ0008.4 4. 1. 縺0007060207 0906 02080ｸ70ｹ0 000ｸ70ｹ0 60 6ｾ404. 4. 1. ﾒ 02 0402000ｸ76ｧ8 02080ｸ7 000ｸ7. 6ﾒ20308apple08apple08060900 閨0708 applefi 0208:
13K00080703 0608 4 6ｾ402fi04080ｹ0 02080ｸ7 020002070302080ｸ7 020008 03 6ｧ9080ｸ7 006ｧ907 06 08 00 0309026ｧ80ｹ0 07 0007030006 02 0307 020807 0402000300020602fi 000ｸ7, 02060ｹ0 06 06fi020902 閨0ｹ0 02080ｸ7, 02
untitled
136ﾑ80303090706026ｧ8 03000803080308096ｧ9 2010; 22 (4): 00-00 ﾞ07 0402fiapple090409 ﾇ 000002 00fi0404000ｸ70409 07000803086ｦ0 0400 04030007006ｧ90ｹ0 0000090703090ｹ0 090306026ｧ9 0ｹ0 0402060ｹ0 0304 閨0ｹ0 02090ｹ0
2000_1852_Testo EL
13 13 13 ﾒ 02070302060409 02 06 000703090409 0000 0402fi0408 020907 applefi0202090409 0602 0708026ｧ8020ｷ307 04006ｦ002000309 閨0203000409 0906 020907 閨03000ｸ707 04040002060207 0000 020907 00apple 0909000300
¢éïîùóÞðïùìï÷ 1è 2005 óåì. 10
13 ﾌ 08070206026ｧ8 01000603080ｸ7030906026ｧ8 6ｾ4TOMA 2005; 33 : 39 ｨC 48 08066 50306080903 0806026ｧ8 07 0402fiapple090409 ﾇ 0203060706026ｧ8 07020600000206apple060409 02090ｹ0 080306 026ｧ80ｹ0 0006020308 06006ｧ904
2/A BAKAS p24
132 KE02A AIO A H EITOYP 紵A T03N MY03N TOY KOPMOY 6ｾ4E Y 紵EI6ｾ4 KAI 6ｾ4E ATOMA ME A 絨6ｾ4 6ｾ4THN O6ｾ402Y E.H. M09AKA6ｾ4 O 02080300fi0ｹ0 apple08020003006ｧ9 020807 026ｦ0030608 040ｸ707 00020602fi 02036ｧ90208
untitled
136ﾑ8apple6ｧ9apple00 縺030ｷ30404080007030006 0ｹ0 04020907 6ﾑ80303090706026ｧ8 0ｷ30ｹ0 04006ｦ002000309 縺03060404 136ﾑ8096ﾑ8 ﾞ6ﾑ8 ﾒ - 罍ｯ ﾒ096ｾ4 09010807 0ｹ0 1 09 閨020308 1. 1 6ﾑ807 閨03090006 1. 1.1. 0903080903070000
Laibman Mΐςλετ
13David Laibman 131 A09080307 02 06 040400 06 0400fi0ｹ0: H 0001 閨03060109 020ｷ307 04080406 0306040206020607 020806070ｷ30706020607 08000607 04020907 06040208036ｧ9 02 06 0209 03000ｷ3036ｧ9 6ｾ402060ｹ0 0304
untitled
09 030709080702000ｹ0 020607 6ｦ007080ｸ7 0ｸ7apple08020308apple6ｧ80ｹ0 02 06 09 (00fi07060009) 020607090208apple086ｧ9090409 020ｷ307 080702060607 0ｷ30ｹ0 00 閨0408 040ｸ709020307020904090ｹ0 02080ｸ7 apple08020003
ｹ0 1. 6ﾑ ｷ3096ｧ8 ﾇ ｧ9 0ｸ7026ｧ8 00apple ｧ fiapple ｹ ｧ9 0ｹ0
13 ﾌ 080702060708040ｷ3030907070306 02 06 apple080308fi0ｹ0 ﾒ0806ｦﾐ ﾌ ﾒ ﾞ6ﾒ26ﾑ808050803 ﾌ096ﾑ803 ﾌ ﾞ060506 ﾌ ﾌ 080702060708040ｷ3030907070306 : 08 03fi03080ｹ0 02080ｸ70ｹ0 04020907 07026ｧ9 03 0409 02080ｸ7 040ｸ700apple03
00 – exofylo
O06020807080006026ｧ8 02036ｧ90409 02 06 0602 6ｧ90ｷ300 04020907 0ｸ709006ｧ9. H apple030804 閨0909060409 020ｷ307 0703030ｷ3apple6ｧ9070ｷ307 0602 060ｷ30007020ｷ307 Mapple08090804060707 E0ｸ7 090900036ｧ9 6ｾ40208applefi0ｹ0
untitled
1309 06 06 020306026ｧ8 BO06EIO08 6ﾑ8 A04 ﾌ6ｾ4, 18: 119-131, 2006 ﾞ03 ﾞ6ｾ4 ﾒ ﾌ09 ﾇ6ｾ4 ﾇ 01036ｧ80409 07020600060203086 506 020607 02 06 0707apple020ｸ70109 070208046ｧ80ｹ0 02080ｸ7 apple07000ｸ700080706fi02080202080ｸ7
(santel)
130903fi030809080ｹ0 0906 020907 000303090706026ｧ8 閨02 080409 6ｾ4020807 02fi040008 02090ｹ0 00apple0604026ｧ800090ｹ0, fi07000603 02 06 000806070302000ｹ0 040ｸ707 0702060702 06 02 06 apple000306apple03 閨02080702
untitled
136ﾑ80303090706026ｧ8 03000803080308096ｧ9 2011; 23 (1): 15-27 ﾞ07 0402fiapple090409 03 閨000ｹ0 06 0402070400060ｹ0 0906 0209 03000602080ｸ703096ｧ9 02080ｸ7 040ｸ704026ｧ800 02080ｹ0 0300076ｧ907090ｹ0 ｨC 0909000608020007046ｧ907090ｹ0
74E78.pdf
04090006080ｸ703096ｧ8040200 08030ｸ7080803060207 CDs 02 06 MP3s ﾌ 08030ｸ708fi03080ｹ0 00apple 6ｧ9ｨB000603 CDs 00030806 000603070000 0906 020907 000602fi07, 6 5 0406ｨBfi0000070806 040208 030902fi fi0206 0006
66.pdf
00 ﾞ09 ﾌ ﾒ0304ｦﾐ ﾒ ﾌ09 ﾌｦﾐ ﾇ6ｾ46ﾒ26ﾑ803 6ﾒ2 ﾌ DREAMBOX 6ｾ4 ﾞ6ｾ4 0208 00 ﾞapple08020ｷ3 060208apple08066ｧ804020003... Dreambox 04 0ｹ0 00 ﾞapple08020ｷ3 060208apple08066ｧ804020003... 0208 Dreambox 04 0ｹ0 08apple070304080ｸ707
00 – exofylo
O04020008applefi030ｷ30409 02 06 O 0807026ｧ9 0203080ｹ0 縺06 070708apple086ｦ003080ｸ7 A0909000306026ｧ8 1, Z00036 5086ｦ0-B07036 509 02030603 2 H 0804020008applefi030ｷ30409 apple08020003006ｧ9 06 02030602fi apple03fi6
EPIST pdf
13Eapple060402090008070602fi B6ｧ800, T.2, - M0706080ｹ0 2003 O 070402 03080ｹ0 02 06 09 000807 010607: H 08apple0206026ｧ8 090ｷ3076ｧ9 02080ｸ7 apple 06 06086ｦ0 E0ｸ7 090900036ｧ9 罍 03 07070209 閨02020803 0ｹ0
untitled
13O09TIKH TEXNIKH KAI E09IKOIN03NIA: H EITOYP 紵A TH6ｾ4 04IA02HMI6ｾ4TIKH6ｾ4 EIKONA6ｾ4 E03 閨0709 M 閨0306080ｸ7 6ﾑ80604 090ｷ3096ｧ8 H apple 03086ｦ004 000003 閨0209 閨040006 0ｷ30ｹ0 0402fi0408 020907 02 02 07fi090409
01 Kefalaio.QXP
131 6ﾑ800apple08030602 閨0ｹ0 0002 0603006ｧ9000ｹ0 040209 03000ｷ3036ｧ9 02 06 020907 06040208036ｧ9 1.1 05 閨00 02 ﾇ 0001 閨03060109, 08 03fi03080ｹ0 02 06 09 03000ｷ3036ｧ9 02090ｹ0 06000307086ｦ00ｹ0 00apple06040006030900
ºïùîïàðè÷ µïàòï÷, 2ï 2008
130900030608 080702080308096ｧ9 6ｾ4TOMA 2008; 36 : 111 - B066 50306080903 0806026ｧ8 07 0402fiapple090409 H apple00030608 08070206026ｧ8 080300090008076ｧ8 0ｷ30ｹ0 apple 030709080702 0ｹ0 00apple06020607 0ｸ707fi020902
untitled
1309 06 06 020306026ｧ8 BO06EIO08 6ﾑ8 A04 ﾌ6ｾ4, 19: 133-144, 2007 ﾒ ｦﾐ03ｦﾐ ﾒ ﾌ6ﾑ806 罍ﾞ6ｾ4ｦ ﾇ06ｦﾐ ﾞ ﾒ ﾇ 096ﾑ8 6ﾑ8ｦ ﾇ 090003 閨0209 02 06 01060803fi09090409 02090ｹ0 閨020803 04090ｹ0 02080ｸ7 09DR1 09080706 6ｧ9080ｸ7
untitled
134.02 ﾞ ﾞ 罍ﾇ 6ﾒ2 ﾌ08 6ﾒ206 ﾌ09 ﾌ08 6ﾑ809ｦﾐ6ｾ46ﾒ2 ﾇ09 ﾌ03ｦﾐ ﾒ ﾇ6ｾ4 09 ﾇ06 ﾌ02 ﾌ06 ﾇ6ｾ4 ﾇ6ｾ4 096ﾑ8 6ﾒ2 ﾇ 0106 ﾇ6ｾ4 ﾇ 04 ﾇ09 ﾌ6ｾ4ｦﾐ6ﾑ80809 ﾞ6ﾒ20303 ﾞ03 ﾌｦﾐ016ﾒ2 ﾇ6ｾ4 0906 ﾌ6ｾ408 ﾞ6ｾ4 ﾇ6ｾ4 ﾒ ﾞｦﾐ ｦﾐ04060809
ANASTASAKHS
6ﾑ8. ﾞ07 0402 040702090ｹ0, 03. 09 apple 07020ｷ3076ｧ9080ｸ7,. 04 0402 030702090ｹ0, 6ｾ4. 09000408096ｧ902090ｹ0, ﾞ. ﾞ070204 02036ｧ80ｹ0 ﾞ ｯ 09 06000ｸ70206026ｧ8 & 縺0ｸ707 06020803080906026ｧ8 ﾒ03060706026ｧ8 09
ﾇ ﾞ036ﾒ2 ﾇ6ｾ ｦ ｸ7 ｨB06080ｸ ｧ , ap
13: 237-244 096ﾑ806ｦﾐ ﾌ04ｦﾐ ﾒ ﾌ 6ﾒ2 ﾇ6ｾ4 E HNIKH6ｾ4 KTHNｦﾐ ﾞ6ﾒ206ｦﾐ ﾒ ﾇ6ｾ4 ETAIP6ﾑ8IA6ｾ4 2009, 60(3): 237-244 Special article 6ﾑ806 0602fi 0703030308 Management of pain ｨC humane endpoints ｨC euthanasia
untitled
1309 6ﾑ806ｦﾐ 縺06 ﾞ02 ﾇ 096ﾑ806ｦﾐ09ｦ 036ｾ4 ﾇ6ｾ4 6ﾑ8070ｷ3036ｧ90ｹ0 0000080707060409 6ｧ86 5090ｹ0 0400 0208036ｧ9020406 0000 046ｦ007 03080008 Wolf-Hirschhorn ﾞ. 0103060402080808036ｧ9 090ｹ0, 09. 0409000902030607
Welc.Plus1 MyPortf. Greek
13 13090003060004fi000007 0307 0903070000 0906 04 閨07 040003. 3 I. ﾇ apple03fi08 fi0ｹ0 00080ｸ7 0402 ｯ ﾞ090903060207 (Language Passport) 040003. 5 II. ﾇ 00apple 086ｧ8 00080ｸ7 0000 02 ｯ ﾞ090903060207 (Language
Welc.Aboard!1 Port.Greek
13For Greece & Cyprus Elizabeth Gray - Virginia Evans 13090003060004fi000007 0307 0903070000 0906 04 閨07 040003. 3 I. ﾇ apple03fi08 fi0ｹ0 00080ｸ7 0402 ｯ ﾞ090903060207 (Language Passport) 040003. 5 II.
13H 00apple6ｧ ｸ ｦ0 apple ｦ ｹ0 06 apple ｷ3apple0602 閨0ｹ 閨 ｹ0 020ｷ
13Eapple060402090008070602fi B6ｧ800, 02. 5, 02006 503080ｸ7070306080ｹ0 2006 ﾇ 00apple6ｧ9 03 0409 02080ｸ7 0300 02030602086ｦ0 apple 06040706 06086ｦ0 0402060ｹ0 06 apple0308040ｷ3apple0602 閨0ｹ0 0404 閨0400060ｹ0
13340 ﾒ. 6ｾ409. ﾒ0806ｦﾐ ﾞ ﾒ ﾇ6ｾ4, VAN REETH K ｦ ｧ9000ｹ0: ( ) 02080ｸ70ｹ ｦ00ｹ ｧ80ｹ fi07080
13096ﾑ806ｦﾐ ﾌ04ｦﾐ ﾒ ﾌ 6ﾒ2 ﾇ6ｾ4 E HNIKH6ｾ4 KTHNｦﾐ ﾞ6ﾒ206ｦﾐ ﾒ ﾇ6ｾ4 ETAIP6ﾑ8IA6ｾ4 2005, 56(4): 339-349 : 339-349 6ﾑ806 0602fi 0903030308 Special Article H 09036ｧ9apple09 020ｷ307 apple0209070607: 08 03fi03080ｹ0
ä¡° ªËÁÆ°º¸ 4ï 2007
13 ﾞ07 060403090406080308096ｧ9 6ｾ4TOMA 2007; 35 : 291-297 B066 50306080903 0806026ｧ8 07 0402fiapple090409 ﾞapple08020ｸ7046ｧ9 04020907 00apple6ｧ902000ｸ70109 0208apple06026ｧ80ｹ0 07 06040309046ｧ9 0ｹ0 04020907
Καινοτομία Έρευνα και Τεχνολογία. τ.47, Αφιέρωμα: Νέα ευρωπαϊκά προγράμματα για έρευνα, καινοτομία και ανταγωνιστικότητα
1304ｦﾐ09 ﾇ03ｦﾐ ﾞｦﾐ ﾞ 6ﾑ8 ﾒ04 ﾌ6ｾ4 ﾇ TEYXO6ｾ4 47 MAPTIO6ｾ4- A09PI IO6ｾ4 2005 6ﾒ2ｦﾐ09 ﾇ: 0.103 ISSN 1106-9066 6ﾑ8 ﾇ03ｦﾐ ﾒ ﾌ ﾒ6ﾑ8036ﾒ206 ﾌ ﾞ03 ﾞ04ｦﾐ ﾞ03 ﾌ09 ﾇ6ｾ4 ﾒ ﾞｦﾐ03 ﾌ6ﾒ2 ﾌ09ｦﾐ ﾞ6ｾ4 http://www.hrc.gr
BEP 絨Y A6ｾ4 1. T apple 閨 ｷ ｦ004000ｷ307 applefi 040ｸ ｸ707 00fi0000
13I0909OKPATEIA 1999, 3, 3: 99-103 Z0ｷ30702 07fi0ｹ0 fi02090ｹ0 07000803086ｦ0 apple080ｸ7 00 040400026ｧ9ｨB0002 06 0900070002060207 0000 020807 036ｧ8apple0209. B 閨0309080ｸ703 0ｹ0 X000603080ｸ7030906026ｧ8 K03060706026ｧ8
41/Z PATSIAOURAS p300
1341 KE02A AIO ﾆ 6ｾ4Y 絳PITIKH ME ETH T03N ME05O0403N A09OKATA6ｾ4TA6ｾ4H6ｾ4 META O IKH 6ｾ409ON04Y EKTOMH 6ｾ4TH 0503PAKOO6ｾ402Y07KH MOIPA TH6ｾ4 6ｾ409ON04Y IKH6ｾ4 6ｾ4TH H6ｾ4 05. 09AT6ｾ4IAOYPA6ｾ4 040607080803000ｹ0
ｧ8 B ﾌ066ﾑ8I ﾌ08 6ﾑ8 ﾞ04 ﾌ6ｾ4, 17, ﾑ ｷ3096ｧ8 6ﾒ apple000604fi 06 (056ﾑ8) 006ｧ907 0
1309 06 06 020306026ｧ8 BO06EIO08 6ﾑ8 A04 ﾌ6ｾ4, 17: 86-90, 2005 096ﾑ806ｦﾐ 縺06 ﾞ02 ﾇ 096ﾑ806ｦﾐ096ﾒ2036ｾ4 ﾇ6ｾ4 050308006 50800006 50803060207 00apple000604fi 06 0400 apple 06 0607 0000 0600 02080308090602
untitled
13E066ﾑ80803 ﾇｦ ｦﾐ ﾒ ﾇ 096ﾑ8 6ﾑ8ｦ ﾇ M0003 閨0209 0002026ｧ9000904090ｹ0 02080ｸ7 0009020008 030602086ｦ0 07 020306080ｸ70309020602086ｦ0 apple00apple0206 6ｧ9080ｸ7 (026ｦ0apple080ｸ7-ｦﾌ) 0ｷ30ｹ0 006ｧ9020209 02 03
KASSANOS teliko
01. ﾒ 0303060702 閨0309, 04. ﾒ 04040707080ｹ0, 6ﾑ8. 6ｾ4 03 00 03 閨02090ｹ0. 罍ｯ 09 06000ｸ70206026ｧ8 02 06 縺0ｸ707 06020803080906026ｧ8 ﾒ03060706026ｧ8 09 0700apple06040209006ｧ9080ｸ7 ﾞ0309070607, 09..03. 00 ﾞ6ﾒ26ﾒ2ｦﾐ
untitled
136ﾑ80303090706026ｧ8 03000803080308096ｧ9 2008; 20 (2): 139-147 09030ｷ302fi020ｸ7apple09 000309 046ｧ9 H 00apple6ｧ9 03 0409 02090ｹ0 030804080ｸ76 5 0402 026ｧ907090ｹ0 040209 0700080306026ｧ8 03000602080ｸ703096ｧ9
KEΦ. 27 ( )
1327 04IATAPA6ｦ1H EN04OKPINIKH6ｾ4 I6ｾ4OPPO09IA6ｾ4 A09O TO6ｦ1IKE6ｾ4 OY6ｾ4IE6ｾ4 TOY 09EPIBA ONTO6ｾ4 02. X 0304086ｦ003090ｹ0 T 020003000ｸ702 6ｧ9 0403fi0706 040ｸ704040ｷ303006ｦ003090200 00020200076ｧ80ｹ0 6 506-6
検査 ABI ABI 5-10 Nhz 0.9 PAD ABI PAD ABI ABI ABI TBI 0.7 PAD TcPO 2 30 mmhg SPP 30 mmhg ABI ABI PAD 20 mmhg ABI PAD MDCT MRA MDCT MRA in
Online publication December 21, 2010 総 説 特集 : 糖尿病の血管病変を再考する 糖尿病に合併する末梢動脈病変の治療 要旨 : J Jpn Coll Angiol, 2010, 50: 595 602 Key words: peripheral artery disease, endovascular therapy, diabetes 下肢閉塞性動脈硬化症 (PAD)
Book Telos
1322 09030ｷ30208apple 036ｧ80ｹ0 0ｸ7apple0003 03 08040200030807060400fi0ｹ0: ﾞ060206080308096ｧ9 ( 040ｸ7076ｧ80300060ｹ0 00080308 閨0ｹ0) ｨC 0203060706026ｧ8 000602fi07 6ﾑ80ｸ7 090900036ｧ9 09 00 03070209 6ﾑ807 08020306070803fi09080ｹ0,
14/¡ TRIANTAFILLOPOULOS p124
1314 KE02A AIO O PO O6ｾ4 TOY 6ｾ4YN05ETIKOY 09OP0304OY6ｾ4 KEPAMIKOY 036ｾ4 O6ｾ4TIKO Y09OKATA6ｾ4TATO 6ｾ4TH 6ｾ409ON04Y O04E6ｾ4IA I.K. TPIANTA02Y O- 09OY O6ｾ4 T 080402060207 00080404006ｦ000 02 04030904060008apple0806086ｦ00702
_LAPOUSHS
13 ﾇ 0404 閨0409 000002 016ｦ0 02080ｸ7 04006ｧ9020209 0907ｨB 0ｹ0 6ｾ40600 02080ｹ0 02 06 020ｷ307 00apple06apple 陦0ｷ307 020ｷ307 0306apple06 6ｧ90ｷ307 0400 00 030902 閨0ｹ0 090306026ｧ9 0ｹ0 12-15 00020607 apple086ｦ004090ｹ0
02-Mavromatidis
13A0302090306 026ｧ8 Yapple 閨0302 0409 14, 2-3: 98-104, 2005 AN ﾞ6ｾ4 ﾒO09 ﾇ6ｾ4 ﾇ ﾇ 0ｸ7apple 閨0302 0409 040208 000002 6 508030602fi 046ｦ007 03080008 ﾒ. 09 0ｸ7030800 026ｧ9 090ｹ0 6ﾑ8. ﾒ 03080906 07076ｧ9 080ｸ7
本文.indd
CQ ACC/AHA PECO PatientExposure Comparison OutcomePECO low-density lipoprotein cholesterol LDL C cholesterol cholesterol intensive OR agressive CQ target LDL C PubMed Systematic Reviews Clinical Study
NEW SEL_127.pdf
1308096ﾑ806 ﾇ01 ﾌ 縺06 ﾞ02ｦﾐ ﾞ 6ﾒ2 ﾌ09.3, 6ﾒ26ﾑ80801.2, 6ｾ46ﾑ8. 127-140, 2006 08. 6ｾ4. 6ﾒ20407apple 07080ｹ0 09 06000ｸ70206026ｧ8- 縺0ｸ707 06020803080906026ｧ8 ﾒ03060706026ｧ8 09 0700apple06040209006ｧ9080ｸ7
untitled
13ｦﾐ ﾌ08 ｦﾐ ﾌ6ｾ4 2003 09 6ﾒ26ﾑ80801O6ｾ4 47 13EFPIA ANNUAL MEETINGS ATHENS 2003 096ﾑ806ｦﾐ6ﾑ801O096ﾑ803 ﾞ 096ﾑ806ｦﾐ6ﾑ801O096ﾑ803 ﾞ O06 罍ﾞ03036ﾒ2ｦﾐ ﾒ ﾇ 6ﾑ809ｦﾐ6ﾒ206O09 ﾇ EFPIA ANNUAL MEETINGS.............................................040003.3
start final-3
1308 ﾞ6ｾ4ｦﾐ ﾒ6ﾑ86ｾ4 6ﾒ26ﾑ80103ｦﾐ ﾒ6ﾑ86ｾ4 6ｾ46ﾒ2 ﾇ03 ﾌ0605 ﾌ09 ﾞｦﾐ04ｦﾐ ﾒ ﾇ 016ﾑ8ｦﾐ06 ﾌ0806 罔ﾐ ﾒ ﾇ 6ﾒ2 ﾌ ｦﾐ6ｾ401ｦﾐ ﾌ 13MASTER TECHNIQUES IN ORTHOPAEDIC SURGERY Editor-in-Chief Bernard F. Morrey, M.D. Founding
untitled
1309 06 06 020306026ｧ8 BO06EIO08 6ﾑ8 A04 ﾌ6ｾ4, 18: 326-333, 2006 ﾞ03 ﾞ6ｾ4 ﾒ ﾌ09 ﾇ6ｾ4 ﾇ 09 030709080702 0ｹ0 02 06 07fi04080ｹ0 von Willebrand ﾒ. ﾒ 03 04000707090ｹ0, ｦﾐ. ｦ 04070203 ﾞ00 09 06 06 020306026ｧ8
untitled
136ﾑ80303090706026ｧ8 03000803080308096ｧ9 2006; 18 (1): 49-58 09030ｷ302fi020ｸ7apple09 000309 046ｧ9 090003060208076ｧ90206 0400 04030007006ｧ90ｹ0 0ｸ7applefi 6ｾ40ｸ70700046ｧ8 02080309026ｧ8 09000306020807 0ｸ8026ｧ8
00 – exofylo
6ｾ402070400060ｹ0 020ｷ307 0808060209020607 020ｷ307 6ｾ40408030607 Y09006ｧ9 0ｹ0 閨07 070206 020ｷ307 09030602060ｷ300 閨070ｷ307 I0ｷ3 07076ｧ9 080ｸ7 K0ｸ70306 026ｧ8 1, T03fi03 A0300016ｧ9 1, K080406060709 E. A07
ver.
13ｨｬ0501 001 030301 72.4(2) 0511 ｨ 09 6ｦ0000306fl 06 2006 6 707 6ｦ0 ｨｺ00 6ｦ0010ｷ3090700006ｦ0fl 01070202006 709fl: ｨｴ.ｨｨ. 01apple046 702fl01076 5 ｨC 07036 5. apple00 6ｦ0010307apple, 04.04. 0002apple0003076
untitled
5 K 5 3 HP http://www.mhlw.go.jp/bunya/shakaihosho/iryouseido01/taikou03.html 2004 1 2 1 http://www.dm-net.co.jp/calendar/2007/06/005835.php 6 85cm 100cm 2 90cm 2 TG 150mg/dl HDLHDL-C 40mg/dl 130mmHg 85mmHg
8 The Bulletin of Meiji University of Integrative Medicine API II 61 ASO X 11 7 X-4 6 X m 5 X-2 4 X 3 9 X 11 7 API 0.84 ASO X 1 1 MR-angio
7-14 2010 1 1 1 2 1 1 1 2 Fontaine II ASO61 3 API ASO ASO ASO API API KKKKKKKKKK ASO Fontaine II API Received April 14, 2009; Accepted July 16, 2009 I arteriosclerosis obliterans: ASO ASO 50 70 1,2 Fontaine
Annaly1_01ZatevakhinLO
130507090307080007060309 0708080200apple076 506010706 060700076 7apple6ｦ0020909 6 5 070ｷ300000100 020400010ｷ30907006ｦ0020000076 707 0607060307fl0009fl 08000ｹ0000009 08apple09 0300036ｦ000090ｹ00006010706
EXOFILLO stomatologika
13311-318 SEL. 09 SYNODINOS* 12-10-07 14:31 6ｾ400036ｧ9 311 H 閨0109 02080ｸ7 030903 0400086ｦ0 020ｷ307 02026ｦ0030ｷ307 0ｷ30ｹ0 060206080308090602fi0ｹ0 apple 030709080702 0ｹ0 0906 020907 0707apple020ｸ70109 08030308
C/NC : committed/noncommitted
C/NC : committed/noncommitted 110 time post-icd implant 1) The Cardiac Arrhythmia Suppression Trial (CAST) Investigators Preliminary report : Effect of encainaide and flecainide on mortality in a
2013¥Ÿ±πæÓ∑ØΩ√æ∆-≥ª¡ˆ
13C07 00apple086ｦ0000900 002 ｨｨ070ｹ0000304 0107apple00fl? 004 ｨｦ 046ｦ006 006 ｨｦ0600076 5000ｸ800 046ｦ008apple6ｦ06 502000009fl 010 0200076 70708apple0702090200000ｸ800 0307020000090ｷ30ｸ8 012 0200 090ｷ3090006010906
V zashitu..._Ver1
13ｨｬ0501 001 030301 72.4(2) 0511 ｨ 09 6ｦ0000306fl 06 2006 6 707 6ｦ0 ｨｺ00 01070202006 709fl: ｨｴ.ｨｨ. 01apple046 702fl01076 5 ｨC 07036 5. apple00 6ｦ0010307apple, 04.04. 0002apple0003076 5 ｨC 096ｦ003. 07036
untitled
13A060506 ﾌ 6ﾑ8ｦﾐ04ｦﾐ ﾒ ﾌ08 6ﾑ80304ｦﾐ ﾞ026ﾑ806 ﾌ03ｦ ﾌ6ｾ4 6ﾑ86 706 6ｧ90709: 08 02000702030602fi0ｹ0 030ｸ703000604026ｧ80ｹ0 000002 6 50803060400086ｦ0 02080ｸ7 0406 6ｧ803080ｸ7 ｦﾌ. 09 apple 09000ｷ303096ｧ9080ｸ7,
apple ｦ0 09 apple ｦ apple0309apple076 56ｦ fl 0603apple6ｦ
1305ｨｬ00010204ｨｦ00ｨｦ07ｨ ｨｹ ｨ 0500090502ｨｦ00ｨｦ07ｨ ｨｹ, 2009, 6ｧ8 6, 06. 1ｨC18 ｨｬ0501 551.23/21;558.42 07ｨ 05ｨｺｨｦ0700ｨｦ07ｨ 02ｨ ｨｹ ｨｪ00ｨｺ020200ｨｲ040107 ｨ 05ｨｪｨｦｨｮ04ｨ 01ｨｦ05 05ｨｬ0001020402 02ｨｬｨｪ04ｨｦ050501ｨ
JCAS 対象および方法 prospective registry CEA CAS JCAS RCT 2 JCAS TIA minor stroke major stroke mrs CEA CAS 1 3 SPECT case volume CEA CAS 結果
Online publication January 14, 2011 原 著 第 50 回総会シンポジウム 5 日本脳神経血管内治療学会 : 頭頸部 頭蓋内血管に対する血行再建術 本邦における頸動脈治療の前向き登録 (JCAS 研究 ) 1 1 JCAS 要旨 :JCAS 5053 1164 69.8 87 45 CAE 34 CAS 2130 major adverse events CEA 3.2
_02.indd
30, 11-16, 2010 Z Z score Computed tomography ROC analysis 3 CT 1,2 CT 1/3 3 5 CT CT 6 7,8 MCA ASPECTS Alberta Stroke Programme Early CT Score 4 10 CT ASPECTS 50% 9 Z 10 CT Z CT 10 Z Z Z receiver operating
apple ｦ apple apple6 76ｦ ｦ000006ｦ0fl ｦ apple ｦ0apple030
1307026ｦ06 56ｦ0 XII 05ｨｦ090402 010201 ｨｪｨｦｨｪ0200ｨｲ04ｨｦ00 040205ｨ 00ｨ 00 ｨｹ 096ｦ06 509 076 56ｦ0026ｦ0 0300apple036 50ｸ803. 0407 0000 03070300026ｦ0 040309apple6ｦ00300. (ｨ 6ｦ0apple00036ｦ0). ｨｪ000800apple00
ｨｺ02ｨｨ00ｨｪｨｦ apple09apple040ｸ903, 0ｹ ｹ ｷ300apple00 apple6ｦ ｸ ｦ006036ｦ
13050005ｨｪ04ｨ 01 040504ｨｦ07ｨｦ 0402ｨｬｨｮ04ｨｦ07ｨｦ 090004ｨｪｨｺ02 ｨｺ0204 ｨｪ0703 5, 6ｧ8 1, 2009, 0603apple. 27ｨC35 ｨｦ03ｨ ｨｦｨｺ01 ｨｬ0501 611.81:616-033.2:611.637 0200ｨｪ0205ｨｪ02ｨｪｨ ｨｮ000501ｨｦ00 ｨｨｨｦｨｺ02050004ｨ 00
13ｨ 00ｨ 0001ｨ ｨ 00ｨｲ 1:28ｨC3: fl apple fi apple fl0ｸ90ｸ
13771 0100096 76ｦ0 ｨｨapple07apple07016ｦ0 ｨ 00090001090902fl 1 1ｨC3 ｨｹ ｪ066 5fl0ｸ70000000901 ｨ 0009000109090200, 060ｸ800 05040909fl. ｨｹ 0ｸ802 6 5 09096 7006ｦ0000909 6 507090200 016ｦ0006ｦ0026ｦ0 0100 6ｦ0apple6ｦ0
審査報告書（案）
19 83 7 18 628 1 19 8 3 7 18 6 28 30 MI 31 360 21700BZY00247000 5mm CEA 59 mm 2 50% 80 1. 2. 3 19 8 3 [ ] 7 [ ] [ ] [ ] [ ] 18 6 28 [ ] CEA 49mm 50 80 2 4 carotid endarterectomy CEA 1,2 CEA ECST 3 NASCET
SocIss8_09ShtompkaLO
13ｨｪ0007apple09fl. 02000307 0702076 709fl 08 2009 6 7. ｨｨ. ｨｰｨｪｨｦ02ｨｨ0102 05 06ｨｦ01ｨｬ0500 0504ｨ 020204ｨ ｨｹ ｨｨｨｦ050500050400050402ｨｹ 05ｨ ｨ 04ｨｲ. 04ｨｦ050109 ｨｨｨｦ05ｨｦｨｺｨｦｨｪ 05 05ｨｦ09ｨ ｨｦ00ｨｦ07ｨ ｨ ｨｰｨｪｨｦ02ｨｨ0102
13ｨｺ fl 09 ｨｹ fl 016ｦ001 apple000604apple ｦ apple6ｦ fl: fl I ｦ0 08apple07 020
13ｨｺ07060609fl 09 ｨｹ08070009fl 016ｦ001 apple000604apple06 6 5096ｦ0090300076 707 apple6ｦ0096 5090309fl: 05096 702fl 0909 0707I 6 5. 006ｦ0 08apple07 02000304 0707 6 5. 05030903apple0906 ｨｪapple00000900,
untitled
136ﾑ80303090706026ｧ8 03000803080308096ｧ9 2009; 21 (4): 273-281 ﾞ07 0402fiapple090409 0908 08026ｦ00202 0308 02 06 04apple000603 00 0208apple07030006000ｹ0 (09 閨03080ｹ0 I: 09080306 026ｧ8 ﾞ03040602000202080706026ｧ8
Print cc tip sheet
Russian: Pre-K 070401070200000901076 5 046ｦ00ｹ009006ｦ0060300 0ｹ009036ｦ00300 06 0003000309 6 5 apple6ｦ000000003 6 50709apple6ｦ0060300 09 00026ｦ0060300 0ｹ10307 0ｹ06ｦ0060307. ｨｺ6ｦ000000906 6 50709apple6ｦ00603
36:378 第 38 回日本脳卒中学会講演シンポジウム 原著 36: , 要旨 TIA 2 t-pa Key words: stroke registry, stroke subtype, onset-visi
36:378 第 38 回日本脳卒中学会講演シンポジウム 原著 36: 378 384, 2014 1 2 要旨 1999 2012 10 31 29 26 80 30 TIA 2 t-pa Key words: stroke registry, stroke subtype, onset-visit time, chronological change はじめに 4 12 23 27 1 Japan
Ch 1
1305.ｨｨ. ｨｮ6ｦ006076 506010903, 05.01. 050ｸ80601070ｹ00902 1 7 060205ｨ 00ｨ ｨｪｨ 020004000505020004ｨｪ 1306000500ｨｺ0200ｨｲ04ｨｦ00 02070004ｨｪ05ｨｪ05ｨｦ ｨｨｨｦ ｨｦ03ｨｺ02ｨ ｨｦ050204ｨ 04 ｨｬｨｺ0200ｨｲ0501ｨ 09 07ｨｦ05ｨｬ0502ｨｺ05ｨｪ050004040109
1) University Group Diabetes Program: A study of hypoglycemic agents on vascular complica- in patients with adult-onset tions diabetes. I. Design, methods and baseline results. Diabetes 19 (suppl. 2):
1 6ｦ apple apple. 586ｦ76 56ｦ 7 VII 1 III I 11 IV 79. VI V 5 XIV VIII IX 1 apple. 5flｹ91 XIV 9 II XIII XI XII X apple. 16ｦa
15ｨｬ1ｨｦｨｦ7ｨ ｨｹ ｨ 595ｨｦｨｦ7ｨ ｨｹ, 8, 6ｧ8 5, 6. 19 ｨｬ51 551.+58./ 56ｨｦｨｺ9ｨ ｨ, 55ｨｹｨ 1 5 5ｨ ｨｲ1 ( = 6.9) ｨ ｨｪｨｺｨｹ5ｨ, ｨｨｨｺｨｦｨｺ15ｨｦ 7 ｨ ｨ ｨ 5ｨｺ5ｨ ｨｹｨ 5 1ｨｺ151ｨｦ 5ｨｬ1ｨ ｨｮ51ｨｦ 9ｨｪｨｺ 5 1996ｨC5 6 76 7. 8 8 6 7...
9U0564RU_cover
6ﾒ09 0070apple090606ｦ000090ｹ0000600906 0000006 5090907apple 00807000 ﾖ0909 陦ｯ ｰ0 ｨC00076 507 0606 507 080700009076 56ｦ00000 ｦ 0006 ﾖ080 6ﾒ09 0070apple090606ｦ000090ｹ0000600906 0000006 5090907apple LCRR
21-07_後藤論文.smd
2015; 21: 5866 Yoichi Goto: Current status and future perspective of cardiac rehabilitation in Japan. J Jpn Coron Assoc 2015; 21: 5866 I 1 1 3 1 2 3 QOL 2 Fig. 1 1 196070 AMI AMI 1980 AMI CABG comprehensive
Sred.veka 68(4)
13ｨｦ03000005ｨｪ05ｨｦ ｨ 05000205ｨｪｨｲ: 05ｨｦ05050005ｨｪ0502, 02ｨｦ0402ｨｺ07ｨ ｨ, 0104ｨｹ050004ｨ ｨｹ * 05.02. 056ｦ0060ｸ9030900 ｨｦ0504ｨｦ05040100 ｨｴｨｪ02ｨｨ01 ｨｪｨｺ02040506ｨｦｨｺ020209ｨ ｨ ｨｨｨｦ00ｨ ｨｪｨ ｨｮ000501ｨ 07 05ｨｪｨｺｨｬ01ｨｪｨｬｨｺ
2, 12 Figure 1 Various methods of measuring carotid stenosis via ultrasound examination. Figure 2 Incidence of vascular events in medical treatment pa
Online publication January 14, 2011 総 説 第 50 回 総 会 シンポジウム 5 日 本 脳 神 経 血 管 内 治 療 学 会 : 頭 頸 部 頭 蓋 内 血 管 に 対 する 血 行 再 建 術 頸 動 脈 狭 窄 症 の 内 科 治 療 要 旨 : pioglitazone EPA 80 unstable plaque MES CEA J Jpn Coll
13ｨｨ00apple00 006ｦ00ｹ06ｦ ｹ ｦ0036ｦ00ｷ ｦ ｦ0apple ｦ ｦ apple09apple076 56ｦ0000
0207 000200 KX-TS15MX-W 046ｦ0 0700 00070300006ｦ0 6 5 09030804020006000703 090209 0307006ｦ00200000703 000008090300 ｨｦ0600076 5000ｸ800 070800006ｦ00ｷ30909 ｨ 0006030004010ｷ3090ｲ4 0807 0ｹ101060802046ｦ0036ｦ00ｷ30909
13 ｪ07 00apple086ｦ ｸ8 07apple apple6ｦ ｸ803 apple0ｸ ｸ ｦ ｦ0apple ｨC6ｦ ｦ:
13 ｪ07dｨ 0906 ﾂｨｪｨｨｨｺ 67 ｰ6ｦ001 ｦ 040603apple070ｸ9 066 50706 6ｦ0016 56ｦ0apple090403 04apple6ｦ00103090ｹ00006010900 06076 500030ｸ8 0703 08apple07020006060907006ｦ002076 5 02 ｦ 006ｦ00ｹ009006ｦ00ｸ90ｸ70903 09
MNT MNT CVD MNT 1) 2) 3) 4) MNT 1) 1 2 2) MNT MNT MNT MNT 1 1 2 1 % HbA1C 2
2008 American Diabetes Association, et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2008 Jan; 31 Suppl 1: S61-S78.
report.dvi
13ｨC 0000apple060402fi030608 06fi020903 ｱ0ｹ00802fi 03000206010ｸ900 ﾖapple06040209030ｸ900 ｮ03fi03 ﾖapple060402fi030903 ｯapple0802086 70604020ｸ900 ｨC0ｹ10209 0606 040ｹ100 00040903 020803 ｨC 6 701000403060803
econet_02.PDF
13 ｱ0903ｨｹ07086ｧ809 陦ﾖ 04ｨC03ｨC030609 陦ﾖ ｨｹ03010408 ﾖｨｹ ｪ ｪｨC ﾖ0609 ﾖ ｭ 07000303 03 ｨｹ070007 ｯ ｪ ｰ070907 04apple00 020708000009 ｦ 02 ｦ 6 501020ｸ90ｹ0000009 ｦ 6 5 060809060701 0106000309apple00076 707 08apple09apple07
metro_new
13ｨ 060307apple09fl 04060800036ｦ0 02070601076 506010906 030003apple07-08070209030000 6ｦ06 50007 06036ｦ002 07apple6 76ｦ000090ｹ0000706 0ｹ06ｦ00603000ｸ9 06030702090ｷ30ｸ8 ｨｺ0706060909, 0009 01070307apple076
untitled
gold standard CT gold standard 1960 1970 1980 1990 CABG ) New device 2000 DES Cumulative Survival rate 100 90 80 70 60 SVD DVD TVD 96.0 94.5 80.7 n=453 n=220 n=198 91.9 87.4 64.2 50 1 2 3 4 5 6 7 8 9
RU Umbr
1305050400070405ｨｪ05ｨｦ 0303ｨｺｨｦ04ｨｦ05ｨｦ ｨｮ6ｦ0060300 3 ｨ 09 6ｦ00007 0900apple03076 5000ｸ9 ｨ 090604066ｦ0 07apple0906036ｦ0 056 5fl030ｸ803 0807060200 000903 000006 13036 50307apple06030700 08apple6ｦ06 507
RU-Master-text.qxd
130507 00apple086ｦ0000900 056 500 00000900...3 ｨｨapple07000103 0909040ｹ0000009fl 08apple07 020003 6 5 060200apple00 030008 04006ｦ0apple07 00076 707 060703apple04 00090ｹ00006036 56ｦ0 ｪ ｨｺ070606090606010900
apple086ｦ VL ｦ000000ｸ ｦ0apple6ｦ000apple ｦ06 5 6ｦ008086ｦ0apple6ｦ0036ｦ0 4 ｨｨapple09006ｦ
13eng.lsis.biz 00040ｹ0040000 Super Solution apple000400000900 056ｦ00404000ｸ800 6ｦ06 507036ｦ0090ｹ000060900 6 50ｸ80ｸ90ｹ06ｦ00009 1507 00apple086ｦ0000900 VL 12 040709006ｦ000000ｸ800 036ｦ0apple6ｦ000apple09060909
ayout 1
13DocuColor 03 242/252/260 0206ｨｬ 06 apple6ｦ0060409apple0000000ｸ80309 6 5070903070800070603fl0309 050706030408000ｸ806 0ｷ36 50003 02fl 020ｸ9 076 707 0701apple0408000009fl. 050107apple07060300, 016ｦ00ｹ00006036
FizAtm2_09ElanskiiLO
13ｨ ｨ 050005ｨｪｨ ｨｹ ｨｺ0204. 06ｨ ｨ ｨ 0102 02ｨｪ02ｨｦ050600ｨｺ01 ｨ ｨｦ0100020402, 2009, 030703 45, 6ｧ8 2, 06. 218ｨC231 ｨｬ0501 551.510 ｨ 06060200 076 56ｦ00009fl 6ｦ0030307060200apple00076 707 070907006ｦ0 6 5 ｨｺ0706060909
32 1 BRONJ BRONJ II BRONJ BRONJ 4 BP BRONJ 6 1 III BP BRONJ
29 1 31 40 2014 31 Bisphosphonate related osteonecrosis of jaw; BRONJ 2008 4 2012 3 36 98 8 11 19 BRONJ 0 13 2 5 3 1 1 0 BP 4 15 10 5 α-streptococcus 0 BRONJ BRONJ BP I Paget 1 409-3898 1110 2014 1 27
main.dvi
1304 ｪ00020803 00000003 ﾖ040206 04036ｧ9000803 ｦ 000ｹ16 7080303 ﾖ060100000ｸ700 04020900 030002fl02090409 0606 02 01020601080ｹ1 016ｧ809080303 01 0000020903 I. A. 080803066ｧ8010903 ｮ03fi03 ﾖapple060402fi030903
Covers
13ｨｬ0ｹ0apple0008 00000ｹ00006010900 0609060300030ｸ8 066 5fl0909 ｮ98/99 13ｨｬ6 56ｦ0086ｦ000030ｸ800 0ｹ009036ｦ003000209, 6ｦ0030ｸ8 09 6 707060807 6ｦ0! 020ｸ8 apple6ｦ0 0ｸ8 08apple00 0706036ｦ06 5020000000706 006ｦ003
Titel_P-10_RU.fm
13090902apple076 50706 0207030708apple09000300apple P-10 ｨｦ0600076 5000700 apple0401076 507 06036 507 ｨｺｨｬ050501ｨ 09 1303026ｦ06 707 6ｦ0apple0903 056ｦ006 096ｦ0 08070104080104 0ｷ30902apple076 5076 707 0207030708apple09000300apple6ｦ0
sick contact1l
Clinical Question 2017 年 5 月 15 日 分野 : 内分泌テーマ : 治療 19 14 15 18 sick contact1l 170cm/68.8kg, GCSE1V1M5, HR: 120/min, BP: 104/60mmHg, RR: 30/min, SpO 2 : 96%, BT: 38.0 WBC Hb PLT CRP Cr BUN 23400 15.0 35.5
ArmA-OA-manual-RUS.qxp:Arma2-OA-manual
13 130507 00apple086ｦ0000900 ｨｨapple00 0408apple0008 000009fl 2 ｨｬ06036ｦ000076 5016ｦ0 2 00Arma 2: ｨｦ0800apple6ｦ00ｷ309fl ｰ0503apple00026ｦ0 ｱ03 3 1 0603apple6ｦ0006ｦ0 ｨC 2 6ｦ0apple030909 ｨC 4 0ｹ00002076 500016ｦ0
2001 2003 2005 2006 2007 2008
2001 2003 2005 2006 2007 2008 60 etc. http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm 23.5% 2.8% 2.8% 3.4% 30.3% 9.9% 11.5% 15.8% AAN 65
<30332D D8CB492982D FC95E490E690B62D8FAC8FBC96BE90E690B62E706466>
A questionnaire survey on the use of placebo in clinical practice by nurses in Japan 1 1 2 2 1 4 1964 5, 6 1998 GCP 1 School of Nursing, Faculty of Medicine, Toho University 2Faculty of Medical Technology,
untitled
13ｨ 6ｦ00ｸ709036ｦ0 0703 c0702000ｷ36ｦ0 Pilkington Suncool 6ｾ4 ｨｺ0401076 507 06036 507 0807 07 apple6ｦ0 07030100, 03apple6ｦ000060807apple0309apple076 50100 09 03apple6ｦ0000000090ｸ9 13ｨｺ0401076 507 06036 507
胆石症
,. vs 64 .. vs. -, Ransohoff DF, Gracie W. Treatment of gallstones. Ann Intern Med ; 119 : - Halldestam I, Enell EL, Kullman E, et al. Development of symptoms and complications in individuals with asymptomatic